 <p>UniSR Università Vita-Salute San Raffaele</p>	<p>APPLICATION TO ACT AS SUPERVISOR AND RESEARCH PROJECT PROPOSAL</p>	<p>MO 20-5 ed. 02 of 16/01/2026 PO 20 Page 5 of 13</p>
---	--	---

PROJECT

Supervisor: Yuri Matteo Falzone

Title: **Complement-Mediated Mechanisms and Biomarker Discovery in
CIDP: A multicentre, Multiparametric Longitudinal Study**

Curriculum: Neurosciences and Experimental Neurology

Link to the personal page of the
University or relevant hospital site
website:

<https://www.hsr.it/dottori/yuri-falzone>

Description of the Project (max 3,000 characters including spaces)

Background/gap of knowledge


Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated neuropathy characterized by progressive or relapsing-remitting demyelination of peripheral nerves, leading to motor and sensory impairment. Despite advances in diagnosis and treatment, CIDP remains a highly heterogeneous disorder in presentation, disease course, and response to therapy, likely reflecting distinct and still poorly understood pathogenic mechanisms.

CIDP pathogenesis involves both cell-mediated and humoral immune responses. While T-cell and macrophage-mediated processes contribute to segmental demyelination, humoral mechanisms amplify nerve injury through autoantibody deposition and downstream effector pathways. Among these, complement activation has emerged as a key mediator linking antibody binding to tissue damage, supported by increased circulating complement components and deposition in sural nerve biopsies.

However, the role of complement in CIDP and its ability to define clinically distinct subgroups remain unclear. In parallel, the lack of reliable biomarkers limits prediction of disease course and treatment response, and clinical management remains largely empirical.

Rationale and hypothesis

Improved understanding of disease mechanisms and identification of biomarkers will enable more precise, individualized treatment. We hypothesize that complement-mediated mechanisms contribute to nerve injury in a subset of CIDP patients and that integrating longitudinal clinical data with circulating biomarkers and tissue proteomics will allow the identification of predictors of disease activity, progression, and treatment response.

 <p>UniSR Università Vita-Salute San Raffaele</p>	<p>APPLICATION TO ACT AS SUPERVISOR AND RESEARCH PROJECT PROPOSAL</p>	<p>MO 20-5 ed. 02 of 16/01/2026 PO 20 Page 6 of 13</p>
---	--	---

Objectives and specific aims

Primary objective

To identify biomarkers predictive of disease activity, progression, and treatment response in CIDP through an integrated longitudinal and multiparametric approach.

Specific aims

- To longitudinally characterize clinical (INCAT, I-RODS, MRC, grip strength), neurophysiological, and imaging (nerve ultrasound) features;
- To quantify circulating biomarkers of nerve damage (α -tubulin, neurofilaments, periaxin) and complement activation;
- To perform proteomic analysis of sural nerve biopsies to assess complement involvement and identify novel biomarkers to be validated in the longitudinal cohort;
- To develop an in vitro model using iPSC-derived neuronal cultures exposed to patient serum and exogenous complement to investigate pathogenic mechanisms and treatment response.

Expected outcomes

To identify biomarkers associated with disease activity, progression, and treatment response, improving patient stratification and clinical decision-making. To clarify the role of complement in CIDP pathophysiology and its relevance in defining disease subsets.


Integration of clinical, proteomic, and experimental data will enable biomarker validation and provide a platform for investigating mechanisms and therapeutic responses supporting a more personalized approach to CIDP management.

Skills that the student should acquire (max. 600 characters including spaces):

Ability to independently formulate research questions, perform autonomous literature searches, and select appropriate investigative methodologies. Advanced skills in longitudinal clinical research, multimodal phenotyping, and structured database management. Expertise in biomarker analysis, sample processing, proteomics and sural nerve biopsy interpretation. Experience in iPSC-derived neuronal culture models and immunofluorescence assays. Competence in data analysis, integration of clinical and experimental findings, and scientific writing.

References (max. 15)

1. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. *Nat Rev Neurol.* 2011;7(9):507-517. doi:10.1038/nrneurol.2011.121



2. Caballero-Ávila M, Pascual-Goñi E, Lleixà C, Martín-Aguilar L, Collet-Vidiella R, Querol L. The changing landscape of primary autoimmune neuropathies. *Nat Rev Neurol*. 2025;21(10):544-555. doi:10.1038/s41582-025-01133-3
3. Van Den Bergh PYK, Van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. *Eur J Neurol*. 2021;28(11):3556-3583. doi:10.1111/ene.14959
4. Querol LA, Hartung HP, Lewis RA, et al. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. *Neurotherapeutics*. 2022;19(3):864-873. doi:10.1007/s13311-022-01221-y
5. Quast I, Keller CW, Hiepe F, Tackenberg B, Lünemann JD. Terminal complement activation is increased and associated with disease severity in CIDP. *Ann Clin Transl Neurol*. 2016;3(9):730-735. doi:10.1002/acn3.331
6. Stascheit F, Preßler H, Stein K, et al. Aberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy. *Neurol Neuroimmunol Neuroinflammation*. 2026;13(2):e200542. doi:10.1212/NXI.0000000000200542
7. Stascheit F, Roos A, Schroeter CB, et al. Complement profiling of sural nerves in chronic-inflammatory demyelinating polyneuropathy. *Acta Neuropathol (Berl)*. 2025;150(1):32. doi:10.1007/s00401-025-02936-w
8. Allen JA, Eftimov F, Querol L. Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. *Expert Rev Neurother*. 2021;21(7):805-816. doi:10.1080/14737175.2021.1944104
9. Bellanti R, Keh RYS, Keddie S, et al. Plasma periaxin is a biomarker of peripheral nerve demyelination. *Brain*. 2025;148(12):4448-4460. doi:10.1093/brain/awaf234
10. Hayashi T, Nukui T, Piao J, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. *Brain Behav*. 2021;11(5):e02084. doi:10.1002/brb3.2084



11. Clark AJ, Kaller MS, Galino J, Willison HJ, Rinaldi S, Bennett DLH. Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. *Brain*. 2017;140(4):898-913. doi:10.1093/brain/awx012
12. Harschnitz O, Van Den Berg LH, Johansen LE, et al. Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model. *Ann Neurol*. 2016;80(1):71-88. doi:10.1002/ana.24680
13. Krijgsman D, Dijkxhoorn K, De Zeeuw E, et al. IgM Anti-Ganglioside Binding and Complement Activation in an iPSC-Derived Motor Neuron Model for Multifocal Motor Neuropathy. *Neurol Neuroimmunol Neuroinflammation*. 2026;13(1):e200482. doi:10.1212/NXI.0000000000200482